Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information (Tables)

v3.22.2.2
Balance Sheet Information (Tables)
9 Months Ended
Sep. 30, 2022
Balance Sheet Information  
Schedule of of cash and cash equivalents and restricted cash

September 30, 2022

    

(unaudited)

    

December 31, 2021

Cash and Cash Equivalents

$

4,801,616

$

7,854,690

Restricted Cash, Non-current

 

49,037

 

45,000

Total Cash, Cash Equivalents and Restricted Cash

$

4,850,653

$

7,899,690

Schedule of prepaid expenses and other current assets

    

September 30, 2022

    

(unaudited)

December 31, 2021

Prepaid Insurance

$

97,617

$

130,765

Prepaid Research and Development

36,760

319,208

Other

 

125,628

 

156,547

Total Prepaid Expenses and Other Current Assets

$

260,005

$

606,520

Schedule of accrued expenses

September 30, 2022

       

(unaudited)

       

December 31, 2021

Executive Severance

$

666,784

$

200,605

Payroll and Benefits

550,133

737,365

Professional Fees

 

442,605

 

194,425

Clinical Trials

 

124,858

 

168,785

Other

15,630

28,961

Total Accrued Expenses

$

1,800,010

$

1,330,141